Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

Figure 3

CT of the pancreas showing three hyperenhancing lesions which have remained stable 38 months after initiating octreotide. (a) Stable 4 mm tumor in the inferior aspect of the pancreatic tail (blue arrow). (b) Stable lesion in the superior aspect of the pancreatic tail (red arrow). (c) Stable lesion in the pancreatic head.

(a)

(b)

(c)